TTM
$577.22M
YoY change
-212.8%
5Y CAGR
—
Peak year (2025)
$313.75M
Cumulative net income
−$6.84B
Net Income history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: $313.75M
Net Income growth chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: -212.8%
Net Income history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| 2025 | $313.75M | -212.8% | +$591.90M | ||
| 2024 | −$278.16M | -36.8% | +$162.09M | ||
| 2023 | −$440.24M | -61.1% | +$690.91M | ||
| 2022 | −$1.13B | +32.6% | −$278.33M | ||
| 2021 | −$852.82M | -0.6% | +$5.46M | ||
| 2020 | −$858.28M | -3.1% | +$27.84M | ||
| 2019 | −$886.12M | +16.4% | −$124.62M | ||
| 2018 | −$761.50M | +55.1% | −$270.62M | ||
| 2017 | −$490.87M | +19.7% | −$80.77M | ||
| 2016 | −$410.11M | +41.4% | −$120.03M | ||
| 2015 | −$290.07M | -19.5% | +$70.32M | ||
| 2014 | −$360.39M | +303.9% | −$271.17M | ||
| 2013 | −$89.22M | -15.8% | +$16.79M | ||
| 2012 | −$106.01M | +83.9% | −$48.37M | ||
| 2011 | −$57.65M | +32.5% | −$14.13M | ||
| 2010 | −$43.52M | -8.6% | +$4.08M | ||
| 2009 | −$47.59M | +81.3% | −$21.34M | ||
| 2008 | −$26.25M | -69.3% | +$59.22M | ||
| 2007 | −$85.47M | +147.0% | −$50.86M | ||
| 2006 | −$34.61M | -19.4% | +$8.31M | ||
| 2005 | −$42.91M | +31.4% | −$10.26M | ||
| 2004 | −$32.65M | +30.4% | −$7.62M | ||
| 2003 | −$25.03M | +505.2% | −$20.90M | ||
| 2002 | −$4.14M | — | — |
- 2025$313.75M-212.8%
- 2024−$278.16M-36.8%
- 2023−$440.24M-61.1%
- 2022−$1.13B+32.6%
- 2021−$852.82M-0.6%
- 2020−$858.28M-3.1%
- 2019−$886.12M+16.4%
- 2018−$761.50M+55.1%
- 2017−$490.87M+19.7%
- 2016−$410.11M+41.4%
- 2015−$290.07M-19.5%
- 2014−$360.39M+303.9%
- 2013−$89.22M-15.8%
- 2012−$106.01M+83.9%
- 2011−$57.65M+32.5%
- 2010−$43.52M-8.6%
- 2009−$47.59M+81.3%
- 2008−$26.25M-69.3%
- 2007−$85.47M+147.0%
- 2006−$34.61M-19.4%
- 2005−$42.91M+31.4%
- 2004−$32.65M+30.4%
- 2003−$25.03M+505.2%
- 2002−$4.14M—
Net Income values are taken from Alnylam Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Net Income at Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's current net income (TTM) is $577.22M. Net income is the bottom-line profit after all expenses — cost of goods sold, operating expenses, interest, and taxes — are subtracted from revenue. It is the figure used to compute earnings per share (EPS) and is the residual available to shareholders.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
2025's annual net income for Alnylam Pharmaceuticals (ALNY) came in at $313.75M – plunged 212.8% year-over-year.
$313.75M stands as the all-time-high annual net income, posted in 2025, against a low of −$1.13B during 2022.
Alnylam Pharmaceuticals Net Income by Year
Alnylam Pharmaceuticals Net Income 2025: $313.75M
Alnylam Pharmaceuticals net income in 2025 was $313.75M, plunged 212.8% below 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Net Income 2024: −$278.16M
2024's net income for Alnylam Pharmaceuticals came in at −$278.16M, plunged 36.8% below 2023.
Alnylam Pharmaceuticals Net Income 2023: −$440.24M
Alnylam Pharmaceuticals posted net income of −$440.24M in 2023, plunged 61.1% below 2022.
Alnylam Pharmaceuticals Net Income 2022: −$1.13B
In 2022, Alnylam Pharmaceuticals reported net income of −$1.13B, surged 32.6% from 2021. This figure represents the lowest annual value in the available history.
Alnylam Pharmaceuticals Net Income 2021: −$852.82M
Alnylam Pharmaceuticals net income in 2021 was −$852.82M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers by Net Income
Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by their latest net income
| $26.80B | |
| $20.64B | |
| $18.25B | |
| $15.97B | |
| $12.06B | |
| $10.26B | |
| $7.71B | |
| $4.23B |
- $26.80B
- $20.64B
- $18.25B
- $15.97B
- $12.06B
- $10.26B
- $7.71B
- $4.23B
Frequently asked questions
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation